Optogenetics therapy restores light sensitivity in half of retinitis pigmentosa patients in early trial

A small clinical study examined an optogenetics‑based approach for treating retinitis pigmentosa, a genetic disorder that progressively destroys retinal light‑sensing cells and often leads to legal blindness in young adults.

The trial reported that roughly 50% of participants regained some degree of photosensitivity, indicating that the technology can partially restore visual function even in the absence of a cure.

These findings, published in the New England Journal of Medicine, suggest that optogenetics may become a viable therapeutic avenue for patients who cannot benefit from existing gene‑therapy options, though larger studies are needed to confirm safety and efficacy.